Natera, Inc. Investor presentation J.P. Morgan Healthcare Conference January 13, 2026 1 Safe harbor statement This presentation containsforward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Allstatements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our anticipated products and launch schedules, our reimbursement coverage and our product costs, our commercial and strategic partn ...

Core Insights - Natera is a leading diagnostic company specializing in cell-free DNA technology, particularly in prenatal testing and minimal residual disease (MRD) testing [1][2] - The company is experiencing significant developments and advancements in its MRD market penetration and competitive dynamics [2] - Recent announcements indicate a strategic focus on early cancer detection, highlighting the company's commitment to expanding its diagnostic capabilities [3] Company Overview - Natera is recognized as a pioneer in advancing the field of MRD testing, which is crucial for monitoring cancer treatment effectiveness [1] - The company is actively engaging in discussions about its current state and future prospects, indicating a robust operational environment [2] Market Dynamics - There is an emphasis on understanding the competitive landscape and reimbursement developments related to MRD testing, which are vital for the company's growth [2] - The focus on early cancer detection represents a strategic shift that could enhance Natera's market position and broaden its service offerings [3]